A

AbbVie

Global biopharmaceutical company developing medicines

Clinical Research Associate 2

Full-TimeUpdated on 10/15/2026
No salary listed
Junior
Bachelor's
Sofia, Bulgaria
Remote
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A tertiary qualification in a health-related discipline, such as Medical, Scientific, or Nursing, is preferred.
  • At least 1 year of clinically related experience is required, including at least 6 months of clinical research monitoring for investigational drug or device trials.
  • Familiarity with risk-based monitoring, including onsite and offsite monitoring, is required.
  • Advanced knowledge of local regulatory and legal requirements, ICH/GCP Guidelines, and applicable policies is required.
  • Strong cross-functional collaboration skills with internal and external stakeholders are required.
  • Strong planning and organizational skills, and the ability to work effectively in a dynamic environment with competing projects and deadlines, are required.
  • The ability to leverage technology, tools, and resources to provide customer-centric support based on site health is required.
  • Strong interpersonal skills, including written, verbal, active listening, and presentation skills, are required to establish and leverage site relationships and trusted partnerships through engagement, motivation, and training.
  • The ability to use functional expertise with appropriate guidance, apply critical thinking, and exercise good judgment to address clinical site issues is required.
  • Integrity in accordance with AbbVie’s code of business conduct and leadership values is required.
  • The ability to deliver timely, quality outcomes in a fast-paced environment is required.
Responsibilities
  • Serve as the primary point of contact for the investigative site, provide contextual information on clinical trials, connect stakeholders to investigative sites, and strengthen AbbVie’s positioning.
  • Align, train, and motivate site staff and the principal investigator on trial-program goals, protocol, and patient-treatment principles to establish a trusted partnership.
  • Conduct site evaluation, site training, routine monitoring, and site-closure monitoring in compliance with the protocol, monitoring plans, applicable regulations, Good Clinical Practices, ICH Guidelines, AbbVie Standard Operating Procedures, and quality standards, while ensuring study-subject safety and protection.
  • Customize site-engagement strategies for assigned studies, gather local and site insights, and use tools such as the Customer Relationship Management tool to report and track progress and measure impact.
  • Connect study protocols, scientific principles, and clinical-trial requirements to day-to-day trial execution; evaluate and ensure effective recruitment and retention techniques and plans based on the patient disease journey.
  • Develop knowledge of the therapeutic area, asset, clinical landscape, and patient journey to support patient recruitment and protocol compliance.
  • Mentor and train less experienced Clinical Research Associates on aspects of the work and provide input into their development; participate in global or local task forces and initiatives as assigned; carry out other activities assigned by the manager.
  • Continuously assess risk and, in collaboration with the Central Monitoring team, monitor site activities to detect study-performance or patient-safety issues early.
  • Resolve site risk signals, understand site processes, and ensure preventive and corrective action plans are implemented as needed to mitigate risk and promote compliance.
  • Identify, evaluate, and recommend potential investigators and sites on an ongoing basis, including through networking or internal requests to place planned clinical studies with qualified investigators.
  • Ensure the quality and timely submission of data from study sites, including appropriate reporting and follow-up for safety events by site personnel; maintain audit and regulatory-inspection readiness at assigned sites; and manage investigator payments according to executed contract obligations, as applicable.
Desired Qualifications
  • Knowledge of relevant therapeutic-area indications and the ability to understand and apply scientific concepts to clinical-trial conduct are preferred.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 13th, 2026
AbbVie vs Novo Nordisk: AbbVie's $61.2B revenue growth makes it the better 2026 buy

A Motley Fool comparison of AbbVie and Novo Nordisk concludes AbbVie is the better long-term buy in 2026, even though Novo looks cheaper. AbbVie's 2025 revenue rose about 8.6% to $61.2 billion, but net income was $4.2 billion. Novo Nordisk's revenue grew 6.4% to $46.3 billion, with net income of $15.3 billion. Novo trades at 11.7 times forward earnings against AbbVie's 20.2. Analysts expect Novo's 2026 sales to fall about 3% on pricing pressure and rivalry from Eli Lilly. AbbVie is forecast to grow net income to $14.6 billion on $67.2 billion in sales, helped by its $10.9 billion Apogee Therapeutics deal and its Skyrizi and Rinvoq drugs.

Yahoo Finance
Oct 13th, 2026
AbbVie shares at $281.12 trade 43.5% below DCF fair value of $497.77 after pipeline wins

AbbVie shares have climbed to $281.12, up 9.33% in a month and 22.59% so far this year, after a run of clinical and regulatory news. Total shareholder return is 25.85% over one year. The news includes Phase 3 Crohn's disease results for SKYRIZI and RINVOQ, and FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer. AbbVie also released early obesity data for ABBV-295 and Phase 2 atopic dermatitis results for zumilokibart. Simply Wall St's most followed narrative puts fair value at $278.61, leaving the stock 1% overvalued. Its discounted cash flow model estimates $497.77, which would put the shares about 43.5% below fair value. Risks include tighter drug price pressure and faster than expected competition for Skyrizi and Rinvoq.

Yahoo Finance
Oct 13th, 2026
AbbVie vs Eli Lilly: Lilly's 44.7% revenue surge to $65.2B makes it the 2026 pick

A comparison of AbbVie and Eli Lilly favours Eli Lilly for long-term investors, driven by its strong weight-loss and diabetes drug franchise. Lilly's 2025 revenue rose 44.7% to $65.2 billion, with net income of $20.6 billion. AbbVie's revenue grew 8.6% to $61.2 billion, with net income of $4.2 billion, as Skyrizi and Rinvoq replace ageing Humira sales. Lilly trades at a forward price-to-earnings ratio of 33.1x, against 19.8x for AbbVie. Lilly expects 2026 revenue of up to $85.2 billion, helped by Zepbound, Mounjaro and a new pill, Foundayo. AbbVie forecasts 2026 sales of $67.2 billion and net income of $14.6 billion. It is also acquiring Apogee Therapeutics.

Finanzen.net
Oct 12th, 2026
S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated.

S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated. October 12, 2026, 4:00 p.m. Invested in AbbVie years ago: This is how much investors would have earned. Exactly 10 years ago today, trading in the AbbVie share took place on the NYSE. The stock ended the day at USD 61.21. With a USD 100 investment 10 years ago, investors would now have 1.634 AbbVie shares in their portfolio. Calculated using the most recent closing price from October 9, 2026 (USD 276.47), the investment would now be worth USD 451.67. That means the value of the original investment would have increased by 351.67 percent. The market value of AbbVie recently amounted to USD 487.20 billion. Please note that stock splits and dividend payments are not taken into account in the above calculation. finanzen.net editorial team Selected leveraged products on AbbVie. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on AbbVie. | Name | Leverage | KO | Issuer | | Mini Future Long on AbbVie | 4.72 | 239.26 | Morgan Stanley | | Turbo Long on AbbVie | 4.60 | 219.21 | Morgan Stanley | | Mini Future Long on AbbVie | 4.51 | 234.17 | Morgan Stanley | | Turbo Long on AbbVie | 4.31 | 215.06 | Morgan Stanley | | Turbo Long on AbbVie | 4.05 | 210.62 | Morgan Stanley | You can obtain the base prospectus as well as the final terms and the key information documents here: MR42P0, MR2ECS, MR42NZ, MR14JZ, MN9YRD. Please also note the further information** on this advertisement. Risk notice: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.

Yahoo Finance
Oct 11th, 2026
AbbVie's yield hits 2.6%, its lowest since 2018, but dividend growth keeps it an income pick

AbbVie's dividend yield has fallen to about 2.6%, its lowest since early 2018. The drop comes from a share price that has risen faster than the dividend, not from any cut. The drugmaker has raised its dividend for 54 consecutive years, including its time as part of Abbott Labs. The payout is up almost 333% since 2013, while the stock has gained roughly 676%. Growth looks set to continue. Humira's successors, Skyrizi and Rinvoq, are on track for combined 2026 sales of over $29 billion, against Humira's peak of about $22 billion in 2021. If dividend growth matches the past five years' pace, yield on cost could top 4.6% within 10 years. Consensus analyst targets imply only about 5% upside over 12 months.